**Supplementary Table 2. Publication bias and heterogeneity of summarized outcomes**

|  |  |
| --- | --- |
| **Outcomes** | **Publication bias** |
| **Begg (*P* value)** | **Egger (*P* value)** |
| ***gal-3 and cardiovascular adverse events in patients with dilated cardiomyopathy*** | 0.453 |  0.146 |
| ***gal-3 in patients with dilated cardiomyopathy and non-dilated disease***  | 0.117 |  0.022  |

Abbreviation: NA, not available.